Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naive Metastatic Kidney Cancer

X
Trial Profile

A Phase 2 BIOmarker Driven Trial With Nivolumab and Ipilimumab or VEGFR tKi in Naive Metastatic Kidney Cancer

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 28 Mar 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ipilimumab (Primary) ; Nivolumab (Primary) ; Pazopanib (Primary) ; Sunitinib (Primary)
  • Indications Renal cancer; Renal cell carcinoma
  • Focus Biomarker; Proof of concept; Therapeutic Use
  • Acronyms BIONIKK
  • Most Recent Events

    • 18 Feb 2023 Results assessing efficacy results of the second-line (L2) treatment, presented at the 2023 Genitourinary Cancers Symposium.
    • 13 Sep 2022 Results identifying biomarkers of N+/-I efficacy in a comprehensive translational research program characterizing in-situ immune markers in frontline metastatic clear cell renal cell carcinoma .presented at the 47th European Society for Medical Oncology Congress
    • 04 Apr 2022 Results published in the Lancet Oncology
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top